Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People
CPIC Level A pharmacogenetic biomarkers are prevalent in Chinese older adults, with over 40% exposed to actionable gene-drug pairs and 36.5% requiring dose adjustments. These findings highlight the clinical imperative to integrate pharmacogenetic testing into geriatric care, prioritize CYP2C19 and SLCO1B1 testing, and develop region-specific guidelines to mitigate polypharmacy risks. Policymakers and clinicians should consider targeted implementation strategies to optimize prescribing safety and efficacy in aging populations.
Authors
- Zinan Zhao (ORCID: https://orcid.org/0000-0003-0922-090X)
- Xiaowen Hu (ORCID: https://orcid.org/0000-0002-3727-6049)
- Yuxuan Zhao (ORCID: https://orcid.org/0000-0001-7506-1703)
- Xue Wang (ORCID: https://orcid.org/0000-0002-7423-362X)
- Gengchen Wang (ORCID: https://orcid.org/0009-0005-3612-9767)
- Christine Y. Lu (ORCID: https://orcid.org/0000-0002-7550-6837)
- Xiaodong Guan (ORCID: https://orcid.org/0000-0002-1290-3827)
- Xinyi Zhang (ORCID: https://orcid.org/0000-0002-0581-9707)
- Luwen Shi
- Pengfei Jin (ORCID: https://orcid.org/0000-0002-0310-4433)
- Wen‐Liang Dong
- Xiaoyan Nie (ORCID: https://orcid.org/0000-0002-1443-2176)
Institutions
- The University of Sydney (AU)
- Harvard University (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Peking Union Medical College Hospital (CN)
- Harvard Pilgrim Health Care (US)
- Beijing Hospital (CN)
Publication Details
- Journal
- Journal of the American Geriatrics Society
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1111/jgs.70126
- Citations
- 1
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.56